{
    "nct_id": "NCT06050122",
    "official_title": "A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome",
    "inclusion_criteria": "1. The subject must be at least 18 years old at the Screening Visit.\n2. The subject must be confirmed to have a PTCH1 mutation.\n3. The subject must have at least 10 BCCs on the face at Randomization (Baseline/Day 1).\n4. The subject must be willing to abstain from application of any non-study topical medication (prescription or over the counter) to their facial skin for the duration of the trial, except as prescribed by the investigator.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study Investigational Product (IP).\n2. The subject is known to have hypersensitivity to any of the ingredients in the IP formulation.\n3. The subject has uncontrolled systemic disease.\n4. The subject has been treated for invasive cancer within the past 5 years excluding chronic lymphocytic leukemia Stage 0, non-melanoma skin cancer, successfully treated melanoma in situ and Stage I melanoma, Stage I cervical cancer, or ductal carcinoma in situ of the breast.\n5. Inefficacy of previous Hedgehog inhibitor therapy.",
    "miscellaneous_criteria": "Key"
}